Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Section 6 of 6

References

143 sources

  1. Adrichem et al. (2022) (opens in a new tab)
  2. Al-Zuhairy and Jakobsen (2023) (opens in a new tab)
  3. Al-Zuhairy et al. (2020) (opens in a new tab)
  4. Allen and Lewis (2015) (opens in a new tab)
  5. Allen et al. (2018) (opens in a new tab)
  6. Allen et al. (2020) (opens in a new tab)
  7. Allen et al. (2021) (opens in a new tab)
  8. Allen et al. (2024) (opens in a new tab)
  9. Allen et al. (2026c) (opens in a new tab)
  10. Allen et al. (2026d) (opens in a new tab)
  11. Allen et al. (2026e) (opens in a new tab)
  12. ANZCTR ACTRN12622001265763 (opens in a new tab)
  13. ANZCTR ACTRN12624000352505 (opens in a new tab)
  14. Aotsuka et al. (2024) (opens in a new tab)
  15. argenx annual report (2026) (opens in a new tab)
  16. Bamrungsawad et al. (2016) (opens in a new tab)
  17. Blackhouse et al. (2010) (opens in a new tab)
  18. Blein et al. (2025) (opens in a new tab)
  19. Brackx et al. (2026) (opens in a new tab)
  20. Breiner et al. (2014) (opens in a new tab)
  21. Bril et al. (2023) (opens in a new tab)
  22. Broers et al. (2019) (opens in a new tab)
  23. Broers et al. (2021) (opens in a new tab)
  24. Bus et al. (2024) (opens in a new tab)
  25. Bus et al. (2026) (opens in a new tab)
  26. CDA-AMC efgartigimod alfa reimbursement recommendation (2026) (opens in a new tab)
  27. CDA-AMC efgartigimod alfa reimbursement review (2026) (opens in a new tab)
  28. Choi et al. (2024) (opens in a new tab)
  29. ClinicalTrials.gov NCT04281472 (opens in a new tab)
  30. ClinicalTrials.gov NCT06290128 (opens in a new tab)
  31. ClinicalTrials.gov NCT06290141 (opens in a new tab)
  32. ClinicalTrials.gov NCT06858579 (opens in a new tab)
  33. ClinicalTrials.gov NCT06920004 (opens in a new tab)
  34. ClinicalTrials.gov NCT07091630 (opens in a new tab)
  35. ClinicalTrials.gov NCT07647510 (opens in a new tab)
  36. Cook et al. (2023) (opens in a new tab)
  37. Cornblath et al. (2022) (opens in a new tab)
  38. Dalakas (2022) (opens in a new tab)
  39. De Lorenzo et al. (2024) (opens in a new tab)
  40. de Pedro et al. (2026) (opens in a new tab)
  41. Dianthus Therapeutics (2022) (opens in a new tab)
  42. Dianthus Therapeutics (2023) (opens in a new tab)
  43. Dianthus Therapeutics (2024b) (opens in a new tab)
  44. Dianthus Therapeutics (2025a) (opens in a new tab)
  45. Dianthus Therapeutics (2026a) (opens in a new tab)
  46. Dianthus Therapeutics (2026e) (opens in a new tab)
  47. Dianthus Therapeutics (2026g) (opens in a new tab)
  48. Dianthus Therapeutics Form 10-K (2025) (opens in a new tab)
  49. Dianthus Therapeutics Form 10-K (2026) (opens in a new tab)
  50. Dianthus Therapeutics Form 10-Q (2026a) (opens in a new tab)
  51. Dianthus Therapeutics Form 10-Q (2026c) (opens in a new tab)
  52. Dianthus Therapeutics Form 8-K (2026) (opens in a new tab)
  53. Dianthus Therapeutics presentation (2024a) (opens in a new tab)
  54. Dianthus Therapeutics presentation (2024b) (opens in a new tab)
  55. Dianthus Therapeutics presentation (2026a) (opens in a new tab)
  56. Dianthus Therapeutics presentation (2026b) (opens in a new tab)
  57. Dianthus Therapeutics presentation (2026c) (opens in a new tab)
  58. Dianthus Therapeutics presentation (2026d) (opens in a new tab)
  59. Dianthus Therapeutics presentation (2026e) (opens in a new tab)
  60. Divino et al. (2018) (opens in a new tab)
  61. Draak et al. (2014) (opens in a new tab)
  62. Dyck et al. (1986) (opens in a new tab)
  63. Eftimov et al. (2012) (opens in a new tab)
  64. EU Clinical Trials Information System 2024-517529-26-00 (opens in a new tab)
  65. Figueroa et al. (2012) (opens in a new tab)
  66. Gable et al. (2026) (opens in a new tab)
  67. Gammagard Liquid prescribing information (2024) (opens in a new tab)
  68. Gamunex-C prescribing information (2026) (opens in a new tab)
  69. Gokhale et al. (2024) (opens in a new tab)
  70. Guptill et al. (2014) (opens in a new tab)
  71. Guptill et al. (2019) (opens in a new tab)
  72. Guptill et al. (2024) (opens in a new tab)
  73. Hadden et al. (2015) (opens in a new tab)
  74. Hadden et al. (2024) (opens in a new tab)
  75. Hafsteinsdottir and Olafsson (2016) (opens in a new tab)
  76. Hahn et al. (1996) (opens in a new tab)
  77. Hauw et al. (2021) (opens in a new tab)
  78. Hizentra prescribing information (2021) (opens in a new tab)
  79. Hughes et al. (2001) (opens in a new tab)
  80. Hughes et al. (2008) (opens in a new tab)
  81. Hughes et al. (2017) (opens in a new tab)
  82. HyQvia prescribing information (2026) (opens in a new tab)
  83. Jung et al. (2023) (opens in a new tab)
  84. Katzberg et al. (2024) (opens in a new tab)
  85. Koay et al. (2025) (opens in a new tab)
  86. Laughlin et al. (2009) (opens in a new tab)
  87. Layton et al. (2023) (opens in a new tab)
  88. Léger et al. (2013) (opens in a new tab)
  89. Lemmen et al. (2025) (opens in a new tab)
  90. Mahdi-Rogers et al. (2017) (opens in a new tab)
  91. Mallick et al. (2025) (opens in a new tab)
  92. Marsh et al. (2021) (opens in a new tab)
  93. McCrone et al. (2003) (opens in a new tab)
  94. Mehndiratta et al. (2015) (opens in a new tab)
  95. Mengel et al. (2018) (opens in a new tab)
  96. Merkies et al. (2000) (opens in a new tab)
  97. Merkies et al. (2009) (opens in a new tab)
  98. Michaelides et al. (2019) (opens in a new tab)
  99. Min et al. (2025) (opens in a new tab)
  100. Muley et al. (2026) (opens in a new tab)
  101. Murakami et al. (2026) (opens in a new tab)
  102. NICE ID6409 draft guidance (2026) (opens in a new tab)
  103. NICE ID6409 project information (2026) (opens in a new tab)
  104. Nobile-Orazio et al. (2012) (opens in a new tab)
  105. Nobile-Orazio et al. (2025) (opens in a new tab)
  106. Nowacek et al. (2025) (opens in a new tab)
  107. Okonkwo et al. (2025) (opens in a new tab)
  108. Pallada et al. (2026) (opens in a new tab)
  109. Panzyga prescribing information (2021) (opens in a new tab)
  110. Pasangulapati et al. (2017) (opens in a new tab)
  111. Pasnoor et al. (2025) (opens in a new tab)
  112. Privigen prescribing information (2025) (opens in a new tab)
  113. Querol et al. (2021) (opens in a new tab)
  114. Querol et al. (2022) (opens in a new tab)
  115. Querol et al. (2025) (opens in a new tab)
  116. Querol et al. (2026a) (opens in a new tab)
  117. Querol et al. (2026d) (opens in a new tab)
  118. Quint et al. (2024) (opens in a new tab)
  119. Rajabally and Cavanna (2015) (opens in a new tab)
  120. Rajabally et al. (2025) (opens in a new tab)
  121. RMC Trial Group (2009) (opens in a new tab)
  122. Rumsey et al. (2022) (opens in a new tab)
  123. Sanofi (2026) (opens in a new tab)
  124. Sommer et al. (2026) (opens in a new tab)
  125. Stascheit et al. (2025) (opens in a new tab)
  126. Stascheit et al. (2026) (opens in a new tab)
  127. Van den Bergh et al. (2021) (opens in a new tab)
  128. van Doorn et al. (2024) (opens in a new tab)
  129. van Doorn et al. (2026) (opens in a new tab)
  130. van Nes et al. (2011) (opens in a new tab)
  131. van Schaik et al. (2010) (opens in a new tab)
  132. van Schaik et al. (2016) (opens in a new tab)
  133. van Schaik et al. (2018) (opens in a new tab)
  134. van Schaik et al. (2019) (opens in a new tab)
  135. Vanhoutte et al. (2013) (opens in a new tab)
  136. Vissing et al. (2024) (opens in a new tab)
  137. Vu et al. (2026b) (opens in a new tab)
  138. Vyvgart Hytrulo prescribing information (2026) (opens in a new tab)
  139. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026) (opens in a new tab)
  140. WHO Drug Information Recommended INN List 94 (2025) (opens in a new tab)
  141. WHO INN monoclonal antibody nomenclature scheme (2022) (opens in a new tab)
  142. WHO Proposed INN List 132 (2024) (opens in a new tab)
  143. Yang et al. (2026) (opens in a new tab)